Evidence map›Paper›PMID 30267200›Full record

ArticleTargeted oncology2018

Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.

Alice Tzeng, C Marcela Diaz-Montero, Patricia A Rayman, Jin S Kim, Paul G Pavicic, James H Finke, Pedro C Barata, Marcelo Lamenza, Sarah Devonshire, Kim Schach and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Targeted oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Alice TzengCleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA.
C Marcela Diaz-MonteroLerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Patricia A RaymanLerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Jin S KimLerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Paul G PavicicLerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
James H FinkeLerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Pedro C BarataTaussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Marcelo LamenzaTaussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Sarah DevonshireTaussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Kim SchachTaussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Hamid EmamekhooDivision of Hematology and Medical Oncology, University of Wisconsin, Madison, WI, USA.
Marc S ErnstoffRoswell Park Cancer Institute, Buffalo, NY, USA.
Christopher J HoimesUniversity Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Brian I RiniTaussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Jorge A GarciaTaussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Timothy D GilliganTaussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Moshe C OrnsteinTaussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. ornstem@ccf.org.
Petros GrivasTaussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. pgrivas@uw.edu.ORCID 0000-0003-3965-3394
Cleveland Clinic · USCleveland Clinic Lerner College of Medicine · USRoswell Park Comprehensive Cancer Center · USUniversity Hospitals Seidman Cancer Center · USUniversity of Wisconsin–Madison · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe identification of prognostic and/or predictive biomarkers for response to immune checkpoint inhibitors (ICI) could help guide treatment decisions.

objectiveWe assessed changes in programmed cell death-1 (PD1)/PD1 ligand (PDL1) expression in key immunomodulatory cell subsets (myeloid-derived suppressor cells [MDSC]; cytotoxic T lymphocytes [CTL]) following ICI therapy and investigated whether these changes correlated with outcomes in patients with metastatic urothelial carcinoma (mUC). PATIENTS AND

methodsSerial peripheral blood samples were collected from ICI-treated mUC patients. Flow cytometry was used to quantify PD1/PDL1 expression on MDSC (CD33

resultsOf 41 ICI-treated patients, 26 received anti-PDL1 (23 atezolizumab/3 avelumab) and 15 received anti-PD1 (pembrolizumab) therapy. Based on available data, 27.5% had prior intravesical Bacillus Calmette-Guérin therapy, 42% had prior neoadjuvant chemotherapy, and 70% had prior cystectomy or nephroureterectomy. Successive doses of anti-PDL1 correlated with decreased percentage of PDL1

conclusionsTreatment with ICI correlated with distinct changes in PD1/PDL1-expressing peripheral immune cell subsets, which may predict objective response to ICI. Further studies are required to validate immune molecular expression as a prognostic and/or predictive biomarker for long-term outcomes in mUC.

Indexed as

FemaleHumansMaleNeoplasm MetastasisProgression-Free SurvivalUrologic Neoplasms

Identifiers

PMID30267200
OpenAlexW2892952396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.